Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) was the recipient of a significant growth in short interest in December. As of December 30th, there was short interest totalling 156,200 shares, a growth of 39.2% from the December 15th total of 112,200 shares. Based on an average daily volume of 815,400 shares, the short-interest ratio is presently 0.2 days. Currently, 1.7% of the shares of the stock are sold short.
Allarity Therapeutics Stock Performance
NASDAQ:ALLR opened at $0.22 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.47 and a quick ratio of 0.47. Allarity Therapeutics has a 12-month low of $0.20 and a 12-month high of $9.67. The firm has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.81.
Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.42). Equities research analysts predict that Allarity Therapeutics will post -2.17 earnings per share for the current year.
Institutional Trading of Allarity Therapeutics
About Allarity Therapeutics
Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
- Get a free copy of the StockNews.com research report on Allarity Therapeutics (ALLR)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.